MYGN Latest Headlines

Myriad Genetics Signals Growth Ahead with Strong Volume Gains and Strategic Test Launches

Market Chameleon (Tue, 24-Feb 10:37 AM)

Sale of Assurex Health to MYGN Highlights Peter Donato’s Track Record as He Joins Diality’s Leadership

Market Chameleon (Tue, 24-Feb 7:31 AM)

Analysts Are Bullish on Top Healthcare Stocks: Repligen (RGEN), Myriad Genetics (MYGN)

at www.tipranks.com (Tue, 24-Feb 9:31 AM)

Guggenheim Keeps Their Hold Rating on Myriad Genetics (MYGN)

at www.tipranks.com (Tue, 24-Feb 7:06 AM)

Piper Sandler Keeps Their Buy Rating on Myriad Genetics (MYGN)

at www.tipranks.com (Tue, 24-Feb 6:37 AM)

Execution and Reimbursement Risks Undermine Myriad Genetics’ Growth Outlook, Justifying Sell Rating

at www.tipranks.com (Tue, 24-Feb 6:16 AM)

Analysts Offer Insights on Healthcare Companies: Myriad Genetics (MYGN) and Hims & Hers Health (HIMS)

at www.tipranks.com (Tue, 24-Feb 6:00 AM)

Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

at www.benzinga.com (Tue, 24-Feb 5:21 AM)

Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y

at seekingalpha.com (Tue, 24-Feb 4:15 AM)

Myriad Genetics outlines $860M–$880M revenue target for 2026 while advancing cancer care continuum strategy

at seekingalpha.com (Mon, 23-Feb 10:55 PM)

Balancing Emerging Growth Momentum and Ongoing Uncertainty: Justifying a Hold Amid Attractive Valuation

at www.tipranks.com (Mon, 23-Feb 9:45 PM)

Myriad Genetics Non-GAAP EPS of $0.04 beats by $0.06, revenue of $209.8M beats by $2.24M

at seekingalpha.com (Mon, 23-Feb 4:14 PM)

Here are the major earnings after the close Monday

at seekingalpha.com (Mon, 23-Feb 10:00 AM)

Myriad Genetics Q4 2025 Earnings Preview

at seekingalpha.com (Fri, 20-Feb 5:35 PM)